| Name | Title | Contact Details |
|---|
PWNHealth is a national clinician network working to improve early detection and prevention of disease using advanced diagnostics and telehealth. Our model enables safe and easy access to diagnostic testing, ensuring clinical validity, utility, quality consumer education, access to clinicians, and the ability to implement national programs seamlessly. Our solutions provide the clinical, legal, and technological framework to facilitate population-scale testing across key healthcare markets. Through integration with more than 80 CLIA-certified labs and support of over 3,000 test types, we are shaping a new paradigm in healthcare, servicing all 50 states and Puerto Rico. We believe that empowering people with convenient access to clinically actionable testing has the power to change lives, improve outcomes, and create a healthier world. PWNHealth is backed by leading growth equity firms Spectrum Equity and the Blue Venture Fund (BVF).
Our story begins in 2005, with a healthcare professional, Dr. Kathleen Myers. She was hired to help open a new, paperless hospital using multiple EMRs and CPOE. A dedicated emergency medicine physician, she knew that every minute counted and worried that “going paperless” would take valuable time away from patients — which was unacceptable. She challenged herself to find a solution. Her answer was a scribe program. She championed development of this for her emergency department, and scribes quickly became an indispensable part of her practice of medicine. So much so, that Dr. Myers sought the support of like-minded individuals with an entrepreneurial spirit to bring these services to other physicians across the country. This is where the company took root. In 2011, Dr. Myers founded Essia Health (formerly Scribes STAT, Inc.) in Portland, Oregon. As a physician, Dr. Myers’ deep expertise helped her to find the pain points of medical practice —where Essia could be most impactful: premium scribe services and EMR support for healthcare providers. In 2013 she was joined by a leadership team of industry experts to carry out Essia’s mission. The response was tremendous. Today, Essia Health has more than 600 employees partnering with institutions nationwide to empower physicians to focus on the practice of medicine. Recognized as a premier provider of scribe services and EMR support, Essia has won multiple awards for excellence in client satisfaction. We have partnered with multi-state hospital networks, specialty clinics, and multispecialty clinics, and we have managed more than 200 successful EMR Go-Lives. Technological change is important. People are most important. Which is why Essia is proud of a heritage of best-in-class service to help our customers navigate this change effectively. We do this by anticipating and resolving unique challenges with quick, innovative solutions that make technology work for you — and not the other way around! There’s nothing better than working with people who truly speak your language.
The Avalon Health Care Group provides the best skilled nursing homes and elder care.
First Smile Home Health Care is a company that provides home health services in Sunland, California, including nursing, therapy, medical equipment, home health aide, and medical social worker services.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic